Neural and motivational mechanisms of age-related change in emotion regulation: Administrative Supplement

与年龄相关的情绪调节变化的神经和动机机制：行政补充

• 批准号: 10654278
• 负责人: Tammy English
• 金额: $ 37.79万
• 依托单位: WASHINGTON UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-04-15 至 2026-01-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10654278
• 关键词: Address; Administrative Supplement; Adult; Affective; Age; Aging; Alzheimer associated neurodegeneration; Alzheimer' s Disease; Amyloid; Amyloid beta-Protein; Anatomy; Attenuated; Behavior assessment; Behavioral; Biological Markers; Blood; Brain; Cognitive; Collaborations; Communities; Corpus striatum structure; Data; Data Collection; Development; Dimensions; Ecological momentary assessment; Elderly; Emotional; Emotions; Ensure; Facial Expression; Foundations; Functional Magnetic Resonance Imaging; Funding; Glial Fibrillary Acidic Protein; Goals; Grant; Human Resources; Image; Individual; Individual Differences; Influentials; Intervention; Knowledge; Laboratories; Lateral; Life; Literature; Major Depressive Disorder; Mass Spectrum Analysis; Matched Group; Measures; Mental Depression; Mental Health; Mental disorders; Methods; Mission; Modeling; Motivation; Nerve Degeneration; Neurobiology; Nucleus Accumbens; Participant; Pathologic; Pathology; Pathway interactions; Pattern; Personal Satisfaction; Plasma; Play; Population; Prefrontal Cortex; Process; Protocols documentation; Quality of life; Recording of previous events; Recurrence; Research; Research Personnel; Research Project Grants; Rewards; Risk; Risk Factors; Role; Sampling; Self-control as a personality trait; Source; System; Testing; Thick; Universities; Update; Variant; Ventral Striatum; Washington; age related; base; blood-based biomarker; cognitive control; cognitive function; cost effective; design; emotion regulation; emotional experience; emotional functioning; experience; healthy aging; improved; individual variation; insight; magnetic resonance imaging biomarker; medical schools; middle age; neuroimaging; neuroimaging marker; neuromechanism; neuropathology; novel; pilot test; positive emotional state; pre-clinical; prevent; prospective; relating to nervous system; response; side effect; single molecule; success; tau Proteins; trait

Project Summary: In the progression from middle to older-age, healthy adults typically experience improvements in their emotional functioning, such as increases in positive emotion and greater expertise in managing emotions. However, not everyone shows these age-related improvements, and the mechanisms that give rise to emotional functioning changes across adulthood are still poorly understood. The primary goal of this project is to examine the critical factors that promote positive emotional development in normative aging, and to test whether depression history might moderate this process as a key trait individual difference marker. To this end, we test our proposed Value-Based Cognitive Control Model of Emotion Regulation in ADulthood (VBCC-MERiAD). The VBCC-MERiAD framework suggests a novel insight: that interactions between reward motivation and cognitive control play a central role in understanding both the normative trajectory of emotional functioning in older adults, and conversely, why and how individuals with depression histories may get “off track”. Our primary hypothesis is that emotion regulation (ER) abilities rely upon the integrity of fronto-striatal circuitry (i.e., activity and connectivity between the lateral prefrontal cortex and nucleus accumbens / ventral striatum), to successfully utilize reward motivation as a means of engaging cognitive control (i.e., to update and maintain ER goals). Across three Specific Aims, we will characterize the mechanisms of ER in middle-aged and older adults (N=220, ages 35-75) using a multi-method design involving functional neuroimaging measures, laboratory behavioral assessments, and experience sampling methods, to identify the neural and behavioral indicators of motivation and cognitive control that predict daily emotional functioning, and potential dysregulation in individuals with depression history. We further propose to enrich our understanding of the mechanisms of age-related change in ER, by capitalizing on recent advances in the ability to assess risk of preclinical Alzheimer’s Disease (AD) and AD-related neurodegeneration through the use of blood plasma-based biomarkers. Through new collaborations with Dr. Suzanne Schindler and Dr. Brian Gordon, our partners at both Washington University, Knight Alzheimer’s Disease Research Center, we will utilize state-of-the-art methods, including single-molecule array (Simoa) and mass spectrometry, to comprehensively assess key blood-based biomarkers related to amyloid (APOE, beta-amyloid), tau (ptau181), and neurodegeneration (NfL, GFAP), as well as anatomical MRI biomarkers (e.g., cortical thickness). We propose an Administrative Supplement to provide additional support for us to acquire, process and rigorously analyze AD- related biomarker data. This Supplement will dramatically enhance the scope and impact of our project, by enabling us to extend our understanding of both normative and dysfunctional age-related change in emotional function, by not only identifying mechanisms that promote positive ER in late adulthood, but also determining the degree to which otherwise undetected preclinical AD moderates such effects. In so doing, we will lay the foundation for new interventions to improve quality of life for older adults and individuals with depression history.

项目摘要：在从中年到老年的过程中，健康成年人通常会经历改善 他们的情绪功能，例如积极情绪的增加和情绪管理方面的专业知识的提高。 然而，并不是每个人都表现出这些与年龄相关的改善，以及引发情绪的机制。 成年期的功能变化仍然知之甚少，该项目的主要目标是检查。 促进正常衰老过程中积极情绪发展的关键因素，并测试是否患有抑郁症 历史可能会作为关键特征个体差异标记来调节这一过程。为此，我们测试了我们提出的建议。 成年情绪调节的基于价值的认知控制模型 (VBCC-MERiAD)。 框架提出了一个新颖的见解：奖励动机和认知控制之间的相互作用发挥着 在理解老年人情绪功能的规范轨迹方面发挥着核心作用，反之亦然， 有抑郁史的人为何以及如何会“偏离正轨”？我们的主要假设是情绪。 调节（ER）能力依赖于额纹状体电路的完整性（即额纹状体之间的活动和连接） 外侧前额皮质和伏隔核/腹侧纹状体），成功地利用奖励动机作为 参与认知控制的方法（即更新和维持 ER 目标），我们将跨越三个具体目标。 使用多种方法描述中老年人（N = 220，年龄 35-75）的 ER 机制 设计涉及功能性神经影像测量、实验室行为评估和经验采样 方法，以确定每日预测的动机和认知控制的神经和行为指标 我们进一步建议有抑郁症史的个体的情绪功能和潜在的失调。 通过利用最新进展，丰富我们对 ER 中与年龄相关的变化机制的理解 通过以下方法评估临床前阿尔茨海默病 (AD) 和 AD 相关神经变性的风险的能力 通过与 Suzanne Schindler 博士和 Brian 博士的新合作，使用基于血浆的生物标记物。 戈登，我们在华盛顿大学和奈特阿尔茨海默病研究中心的合作伙伴，我们将利用 最先进的方法，包括单分子阵列（Simoa）和质谱法，以全面 评估与淀粉样蛋白（APOE、β-淀粉样蛋白）、tau (ptau181) 和相关的关键血液生物标志物 神经退行性变（NfL、GFAP）以及解剖 MRI 生物标志物（例如皮质厚度）。 行政补充文件为我们获取、处理和严格分析 AD- 相关的生物标志物数据将极大地扩大我们项目的范围和影响。 使我们能够扩展对与年龄相关的正常和功能失调的情绪变化的理解 功能，不仅通过识别促进成年晚期 ER 阳性的机制，而且还确定 在此过程中，我们将奠定基础。 寻求新的干预措施来改善老年人和有抑郁症病史的人的生活质量。